Minerva Neurosciences, Inc. (NERV)
NCM · Healthcare · Biotechnology
$4.51
-2.38%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$210.1M
Shares Outstanding
46.6M
Exchange
NCM
Currency
USD
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.4M | -2.8M | -5.0M | -16.7M |
| Net Income | -3.3M | -2.7M | -283.7M | -125.4M |
| Diluted EPS | $-0.43 | $-0.36 | $-25.51 | $-2.86 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -25.2M | -23.1M | -21.8M | -15.1M |
| Net Income | -32.1M | -30.0M | 1.4M | -293.4M |
| Diluted EPS | $-6.01 | $-4.61 | $0.19 | $-34.67 |